SymBio Pharmaceuticals Limited provided consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company expects net sales to be JPY 7,000 million, Operating loss to be JPY 331 million, loss attributable to owners of parent to be JPY 370 million or JPY 9.48 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
170 JPY | -1.16% | -2.30% | -31.17% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.17% | 51.17M | |
+31.52% | 690B | |
+24.31% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+14.21% | 235B | |
+4.61% | 199B | |
-9.94% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- 4582 Stock
- News SymBio Pharmaceuticals Limited
- SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023